Conjunctivitis Market By Type , By Disease Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The conjunctivitis market was valued at $4.8 billion in 2023, and is projected to reach $7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

Conjunctivitis is the most prevalent eye infection that causes the inflammation of the conjunctiva-the thin, transparent membrane that lines the white part of the eye and the inner surface of the eyelids. It can be caused by various factors, including viral or bacterial infections, allergens, or irritants. This condition is characterized by symptoms such as redness, itching, swelling, and discharge from the eye. While often uncomfortable and contagious, conjunctivitis is typically treatable and rarely causes serious complications.

The growth of the global conjunctivitis market is driven by high prevalence of conjunctivitis, particularly in regions with frequent outbreaks, drives demand for treatment and preventive measures. According to a 2024 study published by Medscape-website providing access to medical news, clinical trial coverage, drug updates-an estimated 6 million new cases of viral conjunctivitis occur annually in the U.S. Increase in cases of allergic conjunctivitis due to environmental factors, such as pollution and pollen, boosts the demand for relevant therapies. Moreover, frequent outbreaks of viral or bacterial infections, especially in crowded settings like schools and public transport, foster the need for effective treatment options. Furthermore, increase in preference for over-the-counter eye care products, driven by increased consumer awareness and the convenience of accessing these products without prescription, notably contributes toward the market growth. In addition, surge in geriatric population propels the market growth. This is attributed to the fact that the tissues in the eyes, including the conjunctiva, undergoes natural degeneration. This makes the eyes of aged individuals more prone to irritation, infections, and inflammation, leading to a higher likelihood of developing conditions like conjunctivitis, which augments the demand for specialized treatments. The trend toward personalized medicine is further impacting the conjunctivitis market by promoting tailored treatments based on individual patient profiles and specific conjunctivitis causes. However, many individuals self-diagnose and self-treat conjunctivitis with over-the-counter products or home remedies, which can lead to incorrect treatment and potential worsening of the condition. Misdiagnosis can also result in inappropriate use of medications, which acts as the key deterrent factor of the global market. In addition, limited access to healthcare services and eye care professionals hinders timely diagnosis and treatment of conjunctivitis, leading to higher rates of complications, thus restraining the market growth. On the contrary, advances in pharmaceutical research are leading to the development of new and more effective therapies, including novel antimicrobial agents and anti-inflammatory treatments for conjunctivitis. Furthermore, integration of AI and ML in diagnostic tools to improve the accuracy and speed of conjunctivitis diagnosis and treatment planning is anticipated to offer new avenues for the market growth.

The global conjunctivitis market is segmented into type, disease type, end user, and region. On the basis of the type, the market is bifurcated into diagnosis and treatment. The diagnosis segment is further segmented into physical examination and laboratory tests. The treatment segment is further classified into antibiotics, antiviral, anti-allergic, and artificial tears. Depending on disease type, the market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment is further categorized into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. As per end user, the market is classified into hospitals & clinics, specialty eye clinics, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the treatment segment accounted for the largest share of the market in 2023.

On the basis of disease type, the allergic conjunctivitis segment dominated the market in 2023.

Depending on end user, hospital & clinics emerged as the leading segment in 2023.

Region wise, North America was the major shareholder in the conjunctivitis market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global conjunctivitis market include AFT Pharmaceuticals, Alembic Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Ocular Therapeutics, Inc., Cipla, Inc., Jabs Biotech Pvt. Ltd., Spectra Vision Care Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Grevis Pharmaceutical Private Limited, and Bausch Health Companies Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain strong foothold in the global market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Diagnosis
- Physical Examination
- Laboratory Tests
Treatment
- Antibiotics
- Antiviral
- Anti-allergic
- Artificial Tears

By Disease Type

Allergic Conjunctivitis
- Seasonal Allergic Conjunctivitis
- Perennial Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis

By End User

Hospitals and Clinics
Specialty Eye Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

AFT Pharmaceuticals
Alembic Pharmaceuticals Ltd
Johnson & Johnson Services Inc
Ocular Therapeutics, Inc
Cipla, Inc.
Jabs Biotech Pvt. Ltd.
Spectra Vision Care Pvt. Ltd
Teva Pharmaceutical Industries Ltd
Grevis Pharmaceutical Private Limited
Bausch Health Companies Inc

Product Code: A324393

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: CONJUNCTIVITIS MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Diagnosis
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.2.5. Physical Examination
  - 4.2.5.1. Market Size and Forecast
- 4.2.6. Laboratory Tests
  - 4.2.6.1. Market Size and Forecast
4.3. Treatment
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.3.5. Antibiotics
  - 4.3.5.1. Market Size and Forecast
- 4.3.6. Antiviral
  - 4.3.6.1. Market Size and Forecast
- 4.3.7. Anti-allergic
  - 4.3.7.1. Market Size and Forecast
- 4.3.8. Artificial Tears
  - 4.3.8.1. Market Size and Forecast

CHAPTER 5: CONJUNCTIVITIS MARKET, BY DISEASE TYPE

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Disease Type
5.2. Allergic Conjunctivitis
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.2.5. Seasonal Allergic Conjunctivitis
  - 5.2.5.1. Market Size and Forecast
- 5.2.6. Perennial Allergic Conjunctivitis
  - 5.2.6.1. Market Size and Forecast
5.3. Bacterial Conjunctivitis
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Viral Conjunctivitis
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: CONJUNCTIVITIS MARKET, BY END USER

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
6.2. Hospitals And Clinics
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Specialty Eye Clinics
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Others
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CONJUNCTIVITIS MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Disease Type
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Conjunctivitis Market
  - 7.2.6.1. Market Size and Forecast, By Type
  - 7.2.6.2. Market Size and Forecast, By Disease Type
  - 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Conjunctivitis Market
  - 7.2.7.1. Market Size and Forecast, By Type
  - 7.2.7.2. Market Size and Forecast, By Disease Type
  - 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Conjunctivitis Market
  - 7.2.8.1. Market Size and Forecast, By Type
  - 7.2.8.2. Market Size and Forecast, By Disease Type
  - 7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Disease Type
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Conjunctivitis Market
  - 7.3.6.1. Market Size and Forecast, By Type
  - 7.3.6.2. Market Size and Forecast, By Disease Type
  - 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Conjunctivitis Market
  - 7.3.7.1. Market Size and Forecast, By Type
  - 7.3.7.2. Market Size and Forecast, By Disease Type
  - 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Conjunctivitis Market
  - 7.3.8.1. Market Size and Forecast, By Type
  - 7.3.8.2. Market Size and Forecast, By Disease Type
  - 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Conjunctivitis Market
  - 7.3.9.1. Market Size and Forecast, By Type
  - 7.3.9.2. Market Size and Forecast, By Disease Type
  - 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Conjunctivitis Market
  - 7.3.10.1. Market Size and Forecast, By Type
  - 7.3.10.2. Market Size and Forecast, By Disease Type
  - 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest of Europe Conjunctivitis Market
  - 7.3.11.1. Market Size and Forecast, By Type
  - 7.3.11.2. Market Size and Forecast, By Disease Type
  - 7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Disease Type
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Conjunctivitis Market
  - 7.4.6.1. Market Size and Forecast, By Type
  - 7.4.6.2. Market Size and Forecast, By Disease Type
  - 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Conjunctivitis Market
  - 7.4.7.1. Market Size and Forecast, By Type
  - 7.4.7.2. Market Size and Forecast, By Disease Type
  - 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Conjunctivitis Market
  - 7.4.8.1. Market Size and Forecast, By Type
  - 7.4.8.2. Market Size and Forecast, By Disease Type
  - 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. Australia Conjunctivitis Market
  - 7.4.9.1. Market Size and Forecast, By Type
  - 7.4.9.2. Market Size and Forecast, By Disease Type
  - 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Conjunctivitis Market
  - 7.4.10.1. Market Size and Forecast, By Type
  - 7.4.10.2. Market Size and Forecast, By Disease Type
  - 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Conjunctivitis Market
  - 7.4.11.1. Market Size and Forecast, By Type
  - 7.4.11.2. Market Size and Forecast, By Disease Type
  - 7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Disease Type
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Conjunctivitis Market
  - 7.5.6.1. Market Size and Forecast, By Type
  - 7.5.6.2. Market Size and Forecast, By Disease Type
  - 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Conjunctivitis Market
  - 7.5.7.1. Market Size and Forecast, By Type
  - 7.5.7.2. Market Size and Forecast, By Disease Type
  - 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Conjunctivitis Market
  - 7.5.8.1. Market Size and Forecast, By Type
  - 7.5.8.2. Market Size and Forecast, By Disease Type
  - 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Conjunctivitis Market
  - 7.5.9.1. Market Size and Forecast, By Type
  - 7.5.9.2. Market Size and Forecast, By Disease Type
  - 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. AFT Pharmaceuticals
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Alembic Pharmaceuticals Ltd
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Johnson And Johnson Services Inc
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Ocular Therapeutics, Inc
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Cipla, Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Jabs Biotech Pvt. Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Spectra Vision Care Pvt. Ltd
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Teva Pharmaceutical Industries Ltd
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Grevis Pharmaceutical Private Limited
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Bausch Health Companies Inc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments